ChemBriefAbbVie trims 2026 profit forecast on Apogee buy, beats second-quarter estimates
AbbVie lowered its 2026 profit forecast to account for the $10.9 billion Apogee Therapeutics acquisition while beating Q2 earnings estimates on strong immunology drug sales.
reuters · 2026-07-31 04:50 UTC